Vor Biopharma Quarterly Income Statement
NASDAQ: VORHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
19.90+0.77 (+4.03%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Vor Biopharma revenue and earnings
Vor Biopharma reported a net loss of $62.8 million, compared with a loss of $1.57 billion a year earlier. Diluted earnings per share came in at -$1.16.
Summary generated from market data by MetaCap's automated system. Methodology
Vor Biopharma income statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Expenses | 47.85M | 35.16M | 35.96M | 28.11M | 274.28M | 33.29M | 31.31M | 28.51M | 29.04M | 32.33M | 28.12M | 35.32M |
| Research & Development | 25.92M | 17.59M | 19.19M | 14.14M | 261.50M | 26.70M | 25.35M | 21.82M | 21.82M | 24.32M | 20.90M | 27.61M |
| Operating Income | -47.85M | -35.16M | -35.96M | -28.11M | -274.28M | -33.29M | -31.31M | -28.51M | -29.04M | -32.33M | -28.12M | -35.32M |
| Other Income (Expense) | -14.96M | -184.43M | 1.76B | -784.58M | -1.30B | 805.00K | 599.00K | 954.00K | 1.20M | 1.52M | 1.86M | 2.13M |
| Net Income | -62.81M | -219.58M | 1.72B | -812.68M | -1.57B | -32.49M | -30.71M | -27.56M | -27.84M | -30.80M | -26.26M | -33.19M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | — |
| EPS (Basic) | -1.16 | -5.11 | 307.58 | -121.63 | -251.24 | -5.21 | -25.12 | -8.05 | -0.41 | -0.45 | -0.38 | -0.49 |
| EPS (Diluted) | -1.16 | -5.11 | 307.58 | -121.63 | -251.24 | -5.21 | -25.12 | -8.05 | -0.41 | -0.45 | -0.38 | -0.49 |
| Shares Outstanding (Basic) | 54.30M | 43.01M | — | 6.68M | 6.26M | 6.24M | — | 3.42M | 68.30M | 68.03M | — | 67.61M |
| Shares Outstanding (Diluted) | 54.30M | 43.01M | — | 6.68M | 6.26M | 6.24M | — | 3.42M | 68.30M | 68.03M | — | 67.61M |
| EBITDA | -47.82M | -35.13M | -35.94M | -28.11M | -272.18M | -32.47M | -30.45M | -27.61M | -28.14M | -31.38M | -27.23M | -34.42M |
This table shows 12 quarterly periods of Vor Biopharma's income statement, from Q2 2026 back to Q3 2023, across 10 line items including operating expenses, research & development, operating income. Values in USD; B = billions, M = millions. Fiscal periods follow VOR's reporting calendar. What is a income statement?